Unichem Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Unichem Pharmaceuticals (USA) is a private, commercial-stage generic drug company founded in 1994 and headquartered in Cranbury, New Jersey. As a subsidiary of India's Unichem Laboratories Ltd., it benefits from over 75 years of parent company experience and a vertically integrated supply chain. The company is focused on growing its portfolio of FDA-approved generic products but faces risks typical of the competitive generic sector, including pricing pressure and regulatory compliance, as evidenced by a recent voluntary product recall.

Broad Generic Portfolio

Technology Platform

Vertically integrated generic pharmaceutical manufacturing and distribution model, leveraging in-house Active Pharmaceutical Ingredient (API) production from parent company Unichem Laboratories Ltd.

Opportunities

The large and cost-driven U.S.

generic drug market offers volume growth potential, especially in therapeutic areas with patent expirations or supply shortages.

Vertical integration with API manufacturing provides a competitive edge in cost control and supply chain reliability, which is highly valued by distributors.

Risk Factors

The company operates in a hyper-competitive generic market characterized by severe price erosion.

Regulatory and quality control risks are significant, as evidenced by a recent voluntary product recall, which can damage reputation and incur substantial costs.

Competitive Landscape

Unichem competes against large, established generic pharmaceutical companies like Teva, Sandoz, and Viatris, as well as numerous other generic manufacturers. Competition is primarily based on price, product portfolio breadth, supply reliability, and quality reputation.

More companies in Small Molecule Drugs →More companies in United States →